期刊文献+

地黄合剂对多发性硬化的作用及其作用靶点的研究 被引量:2

Effect of Dihuang on multiple slerosis and its pathway
暂未订购
导出
摘要 目的:观察地黄合剂对多发性硬化患者中枢神经系统中胶质细胞特异性蛋白神经胶质原纤维酸性蛋白和酸性钙结合蛋白表达的影响,探讨地黄合剂在多发性硬化发生发展过程中的作用。方法:用AI,9HPT对多发性硬化患者进行临床评分及分析它们之间的关系,随访3年内经过不同治疗的多发性硬化患者的复发情况,用ELISA法检测多发性硬化患者中枢神经系统中神经胶质原纤维酸性蛋白和酸性钙结合蛋白含量的变化。结果:在多发性硬化组中枢神经系统中神经胶质原纤维酸性蛋白和酸性钙结合蛋白表达明显增强,与正常对照组比较差异有统计学意义,并且与多发性硬化患者的临床评分(AI,9HPT)存在相关性。激素治疗组与未治疗的多发性硬化组比较差异有统计学意义(P<0.05),地黄合剂+激素治疗组与激素治疗组比较差异有统计学意义(P<0.01),同时地黄合剂+激素治疗组对减少多发性硬化的复发次数与单一激素治疗组比较差异有统计学意义(P<0.01)。结论:地黄合剂通过抑制胶质细胞的激活,减少多发性硬化患者中枢神经系统中神经胶质原纤维酸性蛋白和酸性钙结合蛋白的表达,影响多发性硬化的发生和发展及减少多发性硬化患者复发的次数。 Objective To observe the effects of Dihuang on the expression of glial fibrillary acidic protein, S100β in CSF from multiple sclerosis patients, and to explore the role of Dihuang in the development processes of multiple sclerosis. Methods AI and 9HPT scales were used to value the clinical symptoms and the relationship was analyzed. The times of recurring were followed up and recorded in multiple sclerosis patients. The expressions ot glial fibrillary acidic protein and S100β in CSF of multiple sclerosis were detected with ELISA method. Results The expressions of glial fibrillary acidic protein and S100β were stronger in control group than in multiple sclerosis group, hormone therapy group and Dihuang add hormone therapy group, especially than Dihuang add hormone therapy group(P〈0.01). There were correlations between AI and 9HPT clinical scores and the expressions of glial fibrillary acidic protein and S100β in multiple sclerosis patients. There was a statistic difference in decreasing the times of recurring of multiple sclerosis between hormone therapy group and Dihuang add hormone group (P〈0. 01). Conclusion Dihuang, a Chinese medicine, by inhibiting the functions and activation of glial cells in multiple sclerosis, can alleviate the symptoms of multiple sclerosis patients and decrease the times of recurrence, which suggests that Dihuang may be an ideal supplemental medicine in preventing and treating multiple sclerosis.
出处 《实用诊断与治疗杂志》 2007年第5期323-325,共3页 Journal of Practical Diagnosis and Therapy
基金 广东省中医药局项目(项目编号100030) 广东省科技攻关项目(2000年广东省第十三批重点项目30 文件号粤科计字[2000]261) 番禺区科技计划项目(2006-Z-44-1)
关键词 多发性硬化 地黄合剂 神经胶质原纤维酸性蛋白 酸性钙结合蛋白(S100β) Multiple sclerosis glial fibrillary acidic protein S100β
  • 相关文献

参考文献8

  • 1Hemmer B, Kieseier B, Cepok S, et al. New immunopat hologic insight s into multiple sclerosis[J]. Curr Neurol Neurosci Rep,2003, 3(3): 246- 255.
  • 2Polman H, Reingold C, Edan G, et al. Diagnostic Criteria for Multiple Sclerosis: 2000 Revisions to the “McDonald Criteria”[J]. Ann Neurol, 2000,58(4): 840-846.
  • 3高敏,高聪,杨宁.地黄合剂对多发性硬化患者外周血及脑脊液中T淋巴细胞亚群的影响[J].中国中医药科技,2005,12(4):207-208. 被引量:8
  • 4孙怡.中医药防治多发性硬化的研究[J].中医杂志,1997,38(2):113-115. 被引量:7
  • 5Dougherly K D, Dreyfus C F, Black B. Brain derivedneurolrophic faclor in aslrocyles, oligodendrocyles, and microglia/macrophages a fler .spinal cord injury[J]. Neurobiol Dis, 2000, 7(5): 574-585.
  • 6Eng L F, Ghimikar R S, Lee Y L. Glial fibrillary acidic protein:GFAP-thirty-one years (1969 -2000) [J]. Neurochem Res, 2000,25(3): 1439-1451.
  • 7Landar A, Caaddell G, Cgssher J, et al. lndentification of an S100A/S100 target protein, osphoylucomutase[ J]. CellCalcium, 1996, 20(2): 279-286.
  • 8黄长胜 孙丛晓 韩风岳 等.髓复康调节大鼠大脑自由基含量的实验研究.中国中西医结合杂志,2004,24(2):996-998.

二级参考文献20

共引文献13

同被引文献16

  • 1高敏,高聪,杨宁.地黄合剂对多发性硬化患者外周血及脑脊液中T淋巴细胞亚群的影响[J].中国中医药科技,2005,12(4):207-208. 被引量:8
  • 2樊永平.中医药辨证治疗多发性硬化的优势与不足[J].北京中医,2005,24(4):209-211. 被引量:51
  • 3初曙光,沈天真,陈星荣.弥散成像在分析脑多发性硬化病灶病理改变中的价值[J].中华医学杂志,2005,85(35):2513-2517. 被引量:7
  • 4朱潇颖,赵永波.多发性硬化的发病机制[J].上海交通大学学报(医学版),2006,26(10):1190-1192. 被引量:4
  • 5Poser C M, Paty D W, Scheinberg L, et al. New diagnostic criteria for multiple sclero6is. Guidelines for research protocols [ J ]. Ann Neurol, 1983,13 ( 3 ) :227 - 231.
  • 6Roychowdhury S, Maldjian J A, Grossman R I. Multiple sclerosis= comparison of trace apparent diffusion coefficients with MR enhancement pattern of lesions [J]. AJNR Am J Neuroradiol, 2000,21 (5) : 869-874.
  • 7Haselhorst R, Kappos L, Bilecen D, et al. Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended Blood brain barrier leakage correction [J]. J Magn Reson Imaging, 2000,11 (5) : 495-505.
  • 8Mcdonald W I, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis[J]. Ann Neuroi,2001,50(1) :1271-1277.
  • 9Fazekas F, Barkhof F, Filippi M. Unenhanced and enhanced magnetic resonance imaging in the diagnosis of multiple sclerosis [J]. J Neurol Neurosurg Psychiatry,1998,64(Suppl 1):S2-S5.
  • 10李果珍,戴建平,王仪生.临床CT诊断学[M].7版.北京:中国科学技术出版社,2009:366-368.

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部